Mounjaro weight loss plateaus: what TikTok gets wrong

What did @cartcrushuk actually say?

The creator's main argument is that people stalling on tirzepatide (Mounjaro) are probably not eating enough, not too much. Their theory: high doses suppress appetite so aggressively that users accidentally create a "deficit upon a deficit," which triggers a metabolic stall. They recommend calorie tracking, aiming for at least 90g of protein daily, and using a TDEE calculator set to a cutting deficit. They say they personally stalled for six weeks, increased calories, and started losing again.

This is a real phenomenon that gets discussed in weight loss communities constantly, and it's not entirely without basis. But the framing has some problems worth unpacking.

Does the science back this up?

Partially, yes. The appetite suppression data on tirzepatide is striking. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), participants on 15mg tirzepatide lost an average of 20.9% of body weight over 72 weeks, with significant reductions in caloric intake. That level of suppression can absolutely result in very low spontaneous calorie intake, sometimes below what's considered adequate for metabolic function.

The concept of "adaptive thermogenesis" is real and documented. When caloric intake drops too low for too long, resting metabolic rate can fall beyond what's explained by fat loss alone. A study by Rosenbaum and Leibel (2010, Journal of Clinical Investigation) found that aggressive restriction triggers compensatory metabolic slowdown. However, calling this a "metabolic stall" caused purely by under-eating oversimplifies a much messier biological picture. Plateaus on GLP-1 medications have multiple overlapping causes, including physiological adaptation to the drug itself.

What did they get wrong (or right)?

They got the directional advice broadly right: tracking calories and hitting protein targets are sensible practices on any structured weight loss plan. The 90g protein target is conservative but reasonable for many adults. Research consistently supports higher protein intake during caloric restriction to preserve lean mass. A meta-analysis by Leidy et al. (2015, American Journal of Clinical Nutrition) found that protein intakes above 1.2g per kg of bodyweight improved satiety and body composition during weight loss.

What they got wrong is the confidence. Telling someone their stall is probably a "metabolic stall from under-eating" without any clinical context is a guess dressed up as diagnosis. Weight plateaus on tirzepatide can stem from dose adaptation, sleep issues, hormonal factors, actual dietary drift, or just normal physiological variability over time. The creator presents one plausible explanation as if it's the most likely one. It isn't always. Someone genuinely overeating and telling themselves they're not is not well served by this advice.

The recommendation to use a TDEE calculator is reasonable but not a substitute for working with a clinician, especially on a regulated medication like Mounjaro.

What should you actually know?

Weight plateaus are expected, not exceptional. The clinical literature on GLP-1 receptor agonists consistently shows that the rate of loss slows over time even at maximum doses. This is not a failure of the drug or the patient. It is how human metabolism responds to sustained energy deficit.

If you are genuinely tracking calories and eating below 1,000-1,200 kcal per day on Mounjaro, that is worth discussing with your prescribing clinician. Not because a "deficit upon a deficit" is definitively causing your stall, but because very low caloric intake over extended periods raises separate concerns about nutrient adequacy, muscle mass preservation, and bone density. Davies et al. (2021, Lancet) noted that lean mass loss during intensive weight loss programs is a clinically meaningful issue.

The single biggest thing this video gets right is the call to actually track. Most people significantly underestimate portion sizes and intake, and that cuts both ways. You might be eating more than you think, or less. You won't know without data.

• Tirzepatide is a dual GIP/GLP-1 receptor agonist, not simply a GLP-1. Its appetite suppression mechanism is more potent than semaglutide in head-to-head comparisons.
• A weight plateau lasting 4-6 weeks is common and does not automatically indicate a problem requiring a dietary change.
• Any significant changes to your calorie targets or medication approach should involve your prescribing clinician, not a TDEE calculator alone.